Medically Supervised Weight Loss

GLP-1 Medications for Weight Loss

How semaglutide and other GLP-1 agonists work, who qualifies, and what to expect.

6 min readweightmedicationGLP-1

Overview

GLP-1 receptor agonists β€” including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) β€” represent the most significant advance in obesity medicine in decades. Originally developed for type 2 diabetes, these medications work by mimicking gut hormones that regulate appetite, slow gastric emptying, and reduce food cravings. Clinical trials show average weight loss of 15–22% of body weight β€” results previously only seen with bariatric surgery.

Key Points

  • Semaglutide (Wegovy) produces average weight loss of 15% of body weight over 68 weeks in clinical trials.
  • Tirzepatide (Zepbound) β€” a dual GLP-1/GIP agonist β€” produces average weight loss of up to 22% of body weight.
  • GLP-1 medications are FDA-approved for adults with BMI β‰₯30, or β‰₯27 with a weight-related condition.
  • Common side effects are gastrointestinal: nausea, vomiting, constipation β€” usually improve over time.
  • Weight regain is common after stopping β€” these medications work best as part of a long-term management plan.

Signs & Symptoms

  • Indicated for: BMI β‰₯30, or BMI β‰₯27 with hypertension, type 2 diabetes, sleep apnea, or high cholesterol
  • Ideal for patients who have not achieved adequate weight loss with diet and exercise alone
  • Particularly beneficial for patients with type 2 diabetes or prediabetes alongside obesity
  • Appropriate for patients with cardiovascular disease who need weight reduction
  • Not recommended during pregnancy or for patients with a personal or family history of medullary thyroid cancer

Causes & Risk Factors

  • Obesity driven by hormonal dysregulation of appetite and satiety signals
  • Insulin resistance and metabolic syndrome that make weight loss difficult without medical support
  • Failed attempts at sustained weight loss through diet and exercise alone
  • Weight-related comorbidities that increase medical urgency for weight reduction
  • Genetic predisposition to obesity and altered GLP-1 signaling

Treatment Options

1Semaglutide (Wegovy for weight loss; Ozempic for diabetes) β€” weekly subcutaneous injection
2Tirzepatide (Zepbound for weight loss; Mounjaro for diabetes) β€” weekly subcutaneous injection
3Dose titration over 16–20 weeks to minimize gastrointestinal side effects
4Combined with dietary guidance and physical activity for optimal and sustainable results
5Regular follow-up to monitor weight, labs, blood pressure, and medication tolerability

When to See a Doctor

Schedule a weight management consultation to find out if a GLP-1 medication is right for you. We will review your health history, current medications, and goals to determine the best approach. Insurance coverage varies β€” we will help you navigate your options.

This article is for educational purposes only and does not constitute medical advice. Please consult a Lemon-AID Medical Management provider for diagnosis and personalized treatment.